NCHS Data Brief ■ No. 354 ■ January 2020

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Health Statistics

Human Papillomavirus Vaccination Among Adults 

Aged 18−26, 2013−2018

Peter Boersma, M.P.H., and Lindsey I. Black, M.P.H.

Key findings

Data from the National 

Health Interview Survey

● Among adults aged 18−26, 

the percentage who ever 

received one or more doses of 

human papillomavirus (HPV) 

vaccine increased from 22.1% 

in 2013 to 39.9% in 2018. 

● The percentage of adults 

aged 18−26 who received 

the recommended number 

of doses of HPV vaccine 

increased from 13.8% in 2013 

to 21.5% in 2018. 

● In 2018, non-Hispanic white 

adults were more likely than 

Hispanic adults to have ever 

received one or more doses of 

HPV vaccine. 

● Among adults aged 18−26 

who ever received one or more 

doses of HPV vaccine, the 

majority received the first dose 

between the ages of 13 and 

17 years. 

Human papillomavirus (HPV) is a sexually transmitted infection common 

among both men and women (1). HPV vaccination, which requires multiple 

doses, was first recommended for girls in 2006 and for boys in 2011 (2,3). 

Vaccination is routinely recommended at 11−12 years and can be started at age 

9 (4). For those not vaccinated at 11−12 years, vaccination is recommended 

for all persons through age 26 years (4). Two HPV vaccine doses, given 6 to 

12 months apart, are recommended if the series is started before age 15. Three 

doses, to be completed within 6 months, are recommended for those who 

started vaccination at age 15 or over (4,5). This report describes trends in selfreported HPV vaccination initiation and completion by selected demographic 

characteristics among adults aged 18−26.

The percentage of adults aged 18−26 who ever received 

one or more doses of HPV vaccine nearly doubled between 

2013 and 2018.

NCHS reports can be downloaded from: https://www.cdc.gov/nchs/products/index.htm.

0

20

40

60

2013 2014 2015 2016 2017 2018

Figure 1. Percentage of adults aged 18–26 who ever received one or more doses of human 

papillomavirus vaccine, by year and sex: United States, 2013–2018

1

Linear increase during 2013–2018 is statistically significant (p < 0.05). 2

All percentage differences between men and women by year are statistically significant (p < 0.05). 3

Quadtratic increase during 2013−2018 is statistically significant (p < 0.05).

NOTES: Respondents who refused to answer or who answered “Do not know” to the question asking if they had ever received one 

or more doses of human papillomavirus vaccine (6.5% for 2013–2018) were excluded from all analyses. Receipt of vaccination is 

based on self-report. Estimates are based on household interviews of a sample of the civilian noninstitutionalized population. 

Access data table for Figure 1 at: https://www.cdc.gov/nchs/data/databriefs/db354_tables-508.pdf#1.

SOURCE: NCHS, National Health Interview Survey, 2013−2018. Percent

Men3

Women1,2

Total1
NCHS Data Brief ■ No. 354 ■ January 2020

■  2  ■

● Overall, the percentage of adults aged 18−26 who ever received one or more doses of HPV

vaccine increased from 22.1% in 2013 to 39.9% in 2018 (Figure 1). 

● From 2013 through 2018, the percentage of women who ever received one or more doses of 

HPV vaccine increased from 36.8% in 2013 to 53.6% in 2018, and the percentage of men 

more than tripled from 7.7% to 27.0%. 

● For all survey years, women were more likely than men to have ever received one or more 

doses of HPV vaccine. 

The percentage of adults aged 18−26 who received the recommended 

number of doses of HPV vaccine increased from 2013 through 2018. 

● The percentage of adults aged 18−26 who received the recommended number of doses of 

HPV vaccine increased from 13.8% in 2013 to 21.5% in 2018 (Figure 2). 

● The percentage of women who received the recommended number of doses of HPV vaccine 

increased from 25.7% in 2013 to 35.3% in 2018, and the percentage of men increased from 

2.0% in 2013 to 9.0% in 2018.

● For all survey years, women were more likely than men to have received the recommended 

number of doses of HPV vaccine. 

Figure 2. Percentage of adults aged 18–26 who received the recommended number of doses of human papillomavirus 

vaccine, by year and sex: United States, 2013–2018

1

Linear increase during 2013−2018 is statistically significant (p < 0.05). 2

All percentage differences between men and women by year are statistically significant (p < 0.05).

NOTES: A two-dose schedule is recommended for those who start vaccination before age 15, and a three-dose schedule is recommended for those who start at 

age 15 or over. Respondents who refused to answer or who answered “Do not know” to the question asking if they had ever received one or more doses of human 

papillomavirus (HPV) vaccine (6.5% for 2013–2018) were excluded from all analyses. Of the remaining respondents, those who refused to answer or answered 

“Do not know” to either age at first HPV dose (7.9% for 2013–2018) or number of HPV vaccines received (12.5% for 2013–2018) were also excluded from this 

figure. Receipt of vaccination is based on self-report. Estimates are based on household interviews of a sample of the civilian noninstitutionalized population. 

Access data table for Figure 2 at: https://www.cdc.gov/nchs/data/databriefs/db354_tables-508.pdf#2.

SOURCE: NCHS, National Health Interview Survey, 2013−2018. Percent

0

20

40

60

Men1

Women1,2

Total1

2013 2014 2015 2016 2017 2018
NCHS Data Brief ■ No. 354 ■ January 2020

■  3  ■

Overall and for women, non-Hispanic white adults were more likely than 

Hispanic adults to have ever received one or more doses of HPV vaccine.

● Overall, 42.1% of non-Hispanic white, 36.7% of non-Hispanic black, and 36.1% of 

Hispanic adults had ever received one or more doses of HPV vaccine in 2018 (Figure 3). 

● Non-Hispanic white women (57.9%) were more likely to have ever received one or more 

doses of HPV vaccine than Hispanic (48.8%) or non-Hispanic black (44.7%) women.

● Among men, the percentage of adults who had ever received one or more doses of HPV

vaccine ranged from 24.7% among Hispanic men to 29.4% for non-Hispanic black men but 

did not significantly differ by race and Hispanic ethnicity.

● For all race and Hispanic ethnicity groups, women were more likely than men to have ever 

received one or more doses of HPV vaccine.

Figure 3. Percentage of adults aged 18–26 who ever received one or more doses of human papillomavirus vaccine, by 

sex and race and ethnicity: United States, 2018

1

Significantly different from non-Hispanic white adults (p < 0.05). 2

Significantly different from men (p < 0.05).

NOTES: Respondents who refused to answer or who answered “Do not know” to the question asking if they had ever received one or more doses of human 

papillomavirus vaccine (9.1% in 2018) were excluded from all analyses. Receipt of vaccination is based on self-report. Estimates are based on household 

interviews of a sample of the civilian noninstitutionalized population. Access data table for Figure 3 at: 

https://www.cdc.gov/nchs/data/databriefs/db354_tables-508.pdf#3. 

SOURCE: NCHS, National Health Interview Survey, 2018. Percent

0

10

20

30

40

50

60

70

Total Women Men

36.11

42.1

36.7

24.7 26.6

29.4

48.81,2

57.92

44.71,2

Hispanic Non-Hispanic white Non-Hispanic black
NCHS Data Brief ■ No. 354 ■ January 2020

■  4  ■

Among adults who have ever received one or more doses of HPV vaccine, 

age at first HPV dose varied by sex. 

● In 2018, 18.5% of adults who had ever received one or more doses of HPV vaccine received 

their first dose of HPV vaccine at age 12 or under, 25.6% at age 13−14, 34.5% at age 15−17, 

and 21.4% at age 18−26 (Figure 4). 

● Among adults who have ever received one or more doses of HPV vaccine, women (21.9%) 

were more likely than men (11.8%) to have received their first dose of HPV vaccine before 

age 13. 

● Men (27.4%) were more likely than women (18.3%) to have received their first dose of 

HPV vaccine at age 18−26.

Figure 4. Percent distribution of age at first human papillomavirus vaccine dose among adults aged 18–26 who ever 

received one or more doses, by sex: United States, 2018

1

Signficantly different from men for all age groups (p < 0.05).

NOTES: Respondents who refused to answer or who answered “Do not know” to the question asking if they had ever received one or more doses of human 

papillomavirus (HPV) vaccine (9.1% in 2018) were excluded from all analyses. Of the remaining respondents, those who refused to answer or answered “Do not 

know” to age at first HPV dose (17.9% in 2018) were also excluded from this figure. Receipt of vaccination is based on self-report. Estimates are based on 

household interviews of a sample of the civilian noninstitutionalized population. Totals may not add to 100 due to rounding. Access data table for Figure 4 at: 

https://www.cdc.gov/nchs/data/databriefs/db354_tables-508.pdf#4. 

SOURCE: NCHS, National Health Interview Survey, 2018. Percent

0

20

40

60

80

100

18–26 years

15–17 years

13–14 years

12 years or under

Women Men 1 Total

21.4

34.5

25.6

18.5

18.3

30.7

29.2

21.9

27.4

42.0

18.8

11.8
NCHS Data Brief ■ No. 354 ■ January 2020

■  5  ■

Summary 

From 2013 through 2018, the percentage of adults aged 18−26 who reported ever receiving 

one or more doses of HPV vaccine increased from 22.1% to 39.9%, continuing the previously 

documented rise in the percentage of young adults receiving HPV vaccination (6−8). Over the 

same period, the percentage of adults aged 18−26 who received the recommended number of 

doses of HPV vaccine increased from 13.8% to 21.5%. In 2018, receipt of one or more doses 

of HPV vaccine was highest among women and non-Hispanic white adults. Among adults who 

have ever received one or more doses of HPV vaccine, women were more likely than men to 

have received their first dose of HPV vaccine at or before the recommended age of 12. HPV 

vaccination recommendations were issued earlier for girls (2006) compared with boys (2011), 

which may explain differences in age at vaccination by sex (2,3). Monitoring vaccination 

prevalence may help inform strategies to increase HPV vaccination rates.

Definitions

Age at first HPV vaccination: Based on the survey question, “How old were you when you 

received your first HPV shot?”

Human papillomavirus (HPV) vaccination: Based on the survey question, “Have you ever 

received an HPV shot or vaccine?”

Race and Hispanic ethnicity: Based on two separate questions that determine Hispanic or Latino 

ethnicity and race. Persons of Hispanic or Latino ethnicity may be of any race.

Received recommended number of doses of HPV vaccine: Based on the survey question, “How 

many HPV shots did you receive?” For persons first vaccinated before age 15, receipt of two 

doses was considered meeting the recommendation. For persons first vaccinated at age 15 or over, 

receipt of three doses was considered meeting the recommendation. Time between doses was not 

able to be evaluated. 

Data source and methods

Data from the 2013−2018 National Health Interview Survey (NHIS) were used for this analysis. 

NHIS is a nationally representative household survey of the civilian noninstitutionalized U.S. 

population. It is conducted continuously throughout the year by the National Center for Health 

Statistics (NCHS). Interviews are conducted in respondents’ homes, but follow-ups to complete 

interviews may be conducted over the telephone. For more information about NHIS, visit 

https://www.cdc.gov/nchs/nhis.htm.

Information on HPV vaccination was part of the Sample Adult component and was not asked for 

persons under 18. Estimates are of point prevalence, and intention to vaccinate was not captured 

in NHIS. Receipt of vaccination was based on self-report and thus is subject to recall bias. 

Respondents who refused to answer or answered “Do not know” to the question asking if they 

had ever received one or more doses of HPV vaccine (6.5% for 2013−2018; 9.1% in 2018) were 

excluded from all analyses. Of the remaining respondents, Figure 2 also excluded respondents 

who refused to answer or answered do not know to either age at first HPV dose (7.9% for 

2013−2018) or number of HPV vaccines received (12.5% for 2013−2018). Figure 4 also excluded 
NCHS Data Brief ■ No. 354 ■ January 2020

■  6  ■

respondents who refused to answer or answered do not know to age at first HPV dose (17.9% in 

2018). 

The NHIS sample design is described in more detail elsewhere (9). Point estimates and the 

corresponding variances for this analysis were calculated using SUDAAN software (10) to 

account for the complex sample design of NHIS. Differences between percentages were evaluated 

using two-sided significance tests at the 0.05 level. Tests for linear trends were evaluated using 

orthogonal polynomials. All estimates met NCHS presentation standards (11).

About the authors 

Peter Boersma and Lindsey I. Black are with the National Center for Health Statistics, Division of 

Health Interview Statistics.
NCHS Data Brief ■ No. 354 ■ January 2020

■  7  ■

References

1. Centers for Disease Control and Prevention. Genital HPV infection—CDC Fact Sheet. 

Available from: https://www.cdc.gov/std/hpv/HPV-FS-July-2017.pdf.

2. Centers for Disease Control and Prevention. Quadrivalent human papillomavirus vaccine: 

Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 

Recomm Rep 56(RR–2):1–24. 2007.

3. Centers for Disease Control and Prevention. Recommendations on the use of quadrivalent 

human papillomavirus vaccine in males—Advisory Committee on Immunization Practices 

(ACIP), 2011. MMWR Morb Mortal Wkly Rep 60(50):1705–8. 2011.

4. Meites E, Szilagyi PG, Chesson HW, Unger ER, Romero JR, Markowitz LE. Human 

papillomavirus vaccination for adults: Updated recommendations of the Advisory Committee on 

Immunization Practices. MMWR Morb Mortal Wkly Rep 68(32):698–702. 2019.

5. Centers for Disease Control and Prevention. Human papillomavirus (HPV): Vaccine schedule 

and dosing. Available from: https://www.cdc.gov/hpv/hcp/schedules-recommendations.html. 

6. Pazol K, Robbins CL, Black LI, Ahrens KA, Daniels K, Chandra A, et al. Receipt of selected 

preventive health services for women and men of reproductive age—United States, 2011−2013. 

MMWR Surveill Summ 66(20):1–31. 2017.

7. Schmidt S, Parsons HM. Vaccination interest and trends in human papillomavirus vaccine 

uptake in young adult women aged 18 to 26 years in the United States: An analysis using the 

2008–2012 National Health Interview Survey. Am J Public Health 104(5):946−53. 2014. 

8. Centers for Disease Control and Prevention. Vaccination coverage among adults in the United 

States, National Health Interview Survey, 2017. Available from: https://www.cdc.gov/vaccines/

imz-managers/coverage/adultvaxview/pubs-resources/NHIS-2017.html. 2019.

9. National Center for Health Statistics. Survey description, National Health Interview Survey, 

2018. Hyattsville, MD. 2019.

10. RTI International. SUDAAN (Release 11.0.0) [computer software]. 2012.

11. Parker JD, Talih M, Malec DJ, Beresovsky V, Carroll M, Gonzales JF Jr, et al. National 

Center for Health Statistics data presentation standards for proportions. National Center for 

Health Statistics. Vital Health Stat 2(175). 2017.
NCHS Data Brief ■ No. 354 ■ January 2020

Keywords: sexually transmitted infection, HPV, National Health Interview 

Survey

Suggested citation

Boersma P, Black LI. Human papillomavirus 

vaccination among adults aged 18−26, 

2013−2018. NCHS Data Brief, no 354. 

Hyattsville, MD: National Center for Health 

Statistics. 2020.

Copyright information

All material appearing in this report is in 

the public domain and may be reproduced 

or copied without permission; citation as to 

source, however, is appreciated.

National Center for Health 

Statistics

Jennifer H. Madans, Ph.D., Acting Director

Amy M. Branum, Ph.D., Acting Associate 

Director for Science

Division of Health Interview Statistics

Stephen J. Blumberg, Ph.D., Director

Anjel Vahratian, Ph.D., M.P.H., Associate 

Director for Science

For e-mail updates on NCHS publication 

releases, subscribe online at: 

https://www.cdc.gov/nchs/govdelivery.htm.

For questions or general information

about NCHS:

Tel: 1–800–CDC–INFO (1–800–232–4636)

TTY: 1–888–232–6348

Internet: https://www.cdc.gov/nchs

Online request form: https://www.cdc.gov/info

ISSN 1941–4927 Print ed.

ISSN 1941–4935 Online ed.

DHHS Publication No. 2020–1209

CS313615 

U.S. DEPARTMENT OF

HEALTH & HUMAN SERVICES

Centers for Disease Control and Prevention

National Center for Health Statistics

3311 Toledo Road, Room 4551, MS P08

Hyattsville, MD 20782–2064

OFFICIAL BUSINESS 

PENALTY FOR PRIVATE USE, $300

For more NCHS Data Briefs, visit:

https://www.cdc.gov/nchs/products/databriefs.htm.

FIRST CLASS MAIL 

POSTAGE & FEES PAID 

CDC/NCHS

PERMIT NO. G-284